← All trials
NCT04744662
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 8, 2021
- Primary completion
- Dec 30, 2022
- Completion date
- Apr 1, 2023
- First posted
- Feb 9, 2021
- Last posted
- Aug 2, 2021
- Enrollment
- 30
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- ONL TherapeuticsLead sponsor
- Center for Eye Research AustraliaOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.